DPP-4 inhibitor increases GLP-1 and CXCL12 in type 2 diabetes patients with or without DN compared with the placebo group, suggesting its pro-vasculoregenerative ability in type 2 DM [19]. This evidence concerns the gene GLP1R and liver dysplastic nodule.